Participant screening criteria for vitamin D clinical trials

The result is predictable: trials that confound themselves before a single capsule is dispensed.

Vitamin D screening is not a checkbox. It is the biochemical handshake that determines whether the trial measures what the investigators think it measures. Baseline vitamin D status, kidney function, calcium balance, medication exposure, supplement use, and the clinical conditions that shape vitamin D metabolism all belong in the screening conversation. The exact panel depends on the intervention and endpoint, but the principle is constant: eligibility has to be defined before treatment begins, not reconstructed after the data become inconvenient.

The cheapest error in vitamin D research is enrolling participants whose baseline status was never properly characterized, or whose supplement intake was never meaningfully accounted for. Both errors can inflate variance, dilute effect sizes, and manufacture the kind of apparently negative result that gets cited for years. The screening protocol is where this gets fixed — or where it gets papered over.

The Baseline Question Nobody Escapes: Serum 25(OH)D and the Rest of the Panel

For most vitamin D intervention trials, baseline serum 25-hydroxyvitamin D, written as 25(OH)D, is the primary biomarker used to characterize vitamin D status. It is not, however, the only marker that can matter at screening. Calcium, creatinine or estimated glomerular filtration rate, parathyroid hormone, alkaline phosphatase, liver-related measures, pregnancy status, and other safety or eligibility variables may be essential depending on the protocol.

That distinction matters because a trial can use 25(OH)D to define the study population while using other tests to determine whether supplementation is safe or whether the participant's physiology could distort the endpoint. A participant with a low 25(OH)D concentration but unexplained hypercalcemia is not simply an attractive candidate for a repletion study. The low value may coexist with another disorder that changes the risk calculation and the interpretation of treatment response.

The clinical chemistry rationale for 25(OH)D is straightforward. It has a serum half-life measured in weeks, reflects contributions from cutaneous synthesis and dietary intake, and is the principal circulating metabolite used to assess vitamin D stores. By contrast, 1,25-dihydroxyvitamin D — calcitriol, the biologically active hormone — is tightly regulated by parathyroid hormone, calcium, phosphate, and renal physiology. Its concentration can remain normal or change for reasons that do not track overall vitamin D stores. That makes it a poor standalone test for identifying ordinary vitamin D deficiency in most trial-screening settings.

This does not make calcitriol irrelevant. A protocol focused on renal disease, mineral metabolism, unusual endocrine disorders, or a mechanistic endpoint may have a legitimate reason to measure it. The point is narrower and more useful: do not substitute a regulated downstream hormone for the storage-status marker your eligibility criteria actually require.

The same logic applies to safety markers. Serum calcium can identify a risk that 25(OH)D alone will miss. Creatinine or estimated glomerular filtration rate can indicate impaired renal handling of mineral metabolism. PTH can help identify a participant whose calcium–vitamin D axis is already under abnormal regulatory pressure. Alkaline phosphatase may be relevant in bone-focused studies. These tests do not replace 25(OH)D; they answer different screening questions.

Choosing and recording the threshold

Trial thresholds vary, and that variance is itself a research problem. A protocol may define insufficiency below 50 nmol/L, while reserving a lower threshold for more severe deficiency. If severe deficiency is defined as below 25 nmol/L, the approximate conversion is below 10 ng/mL, because 25 nmol/L corresponds to about 10 ng/mL. Likewise, 50 nmol/L corresponds to approximately 20 ng/mL.

These categories are not universal. They shift with the population, study endpoint, season, assay framework, and whether the trial targets a musculoskeletal, immune, metabolic, or other outcome. A cutoff selected for a fracture-related intervention should not automatically be copied into an immune-function protocol. The eligibility criteria for vitamin D studies need to state not only the numerical threshold, but also why that threshold fits the scientific question.

Assay comparability deserves equal attention. A screening value measured by one laboratory method may not be perfectly interchangeable with a value measured by another. Investigators should specify the assay approach, laboratory quality controls, units, and the time between blood collection and randomization. If the trial is stratifying participants by baseline 25(OH)D, a borderline result should not be treated as though it were an exact biological boundary.

Baseline 25(OH)D is usually the anchor of vitamin D screening, but the anchor is not the whole ship. Safety and eligibility markers determine whether that baseline can be interpreted — or whether the participant should be excluded first.

Inclusion Criteria: What Actually Makes Someone Eligible

Inclusion criteria in vitamin D trials often look deceptively simple: a documented baseline 25(OH)D value, written informed consent, and enough metabolic stability to complete the intervention period. The less visible criterion is adherence — the probability that a participant will take the study capsules, attend follow-up visits, report changes in medication and supplement use, and avoid quietly adding a personal vitamin D product halfway through the trial.

You can estimate that probability. You cannot guarantee it.

A defensible recruitment framework usually addresses several layers:

• Age and population definition. Adult participants may be enrolled within a broad age band, while pediatric, geriatric, pregnancy-related, or disease-specific protocols require a different physiological and safety framework. The age range should serve the endpoint rather than function as inherited boilerplate.
• Baseline 25(OH)D within a defined screening window. The result should be recent enough to represent the participant's status at randomization. The acceptable interval depends on the expected stability of the population and whether participants can begin other sources of vitamin D between the blood draw and enrollment.
• Clinical stability. Recent hospitalization, an acute inflammatory illness, major weight change, or a newly altered treatment regimen can make a baseline measurement difficult to interpret. These factors may not always require exclusion, but they should be handled explicitly.
• Medication stability. If a medication can affect vitamin D metabolism, calcium balance, renal function, bone turnover, or the endpoint itself, the protocol should specify whether it must be stable, documented, or excluded.
• Ability to comply with study restrictions. Participants need to understand what happens to personal supplements, fortified products, follow-up testing, and adverse-event reporting once they enter the trial.

Baseline health assessment for vitamin D studies should not be reduced to a single blood value. The screening history can reveal prior fractures, kidney stones, malabsorption, bariatric surgery, liver or kidney disease, endocrine disorders, and treatments that alter vitamin D handling. The relevance of each item depends on the trial, but the screening team should know which conditions are scientifically important and which are safety-critical.

A useful protocol also separates eligibility from stratification. A participant may qualify because their 25(OH)D is below the study threshold, then be stratified by a lower or higher baseline band, season, sex, body size, or disease status. That is often more informative than treating every person below one cutoff as biologically identical.

Exclusion Criteria: The Real Gatekeepers of Trial Validity

Inclusion criteria decide who can enter a trial. Exclusion criteria decide who must stay out — and they do much of the heavy lifting. A vitamin D trial without rigorous exclusions does not recruit a study population. It recruits a confounding factor with a wristband.

The standard exclusion categories fall into four broad groups: safety, pharmacological, physiological, and methodological. The exact thresholds must be set in the protocol and reviewed by the appropriate clinical and ethics teams, but the logic is consistent.

The table is not a universal exclusion checklist. It is a map of the questions a protocol has to answer. For example, a study of bone density may need to treat glucocorticoid exposure as a central confounder, while a short pharmacokinetic study may handle it differently. A trial in chronic kidney disease may include the very participants another protocol excludes, provided the intervention, monitoring, and endpoint are designed for that population.

The most common mistake is to copy exclusion criteria from another trial without copying its scientific rationale. A threshold is not rigorous merely because it appears in a published protocol. It is rigorous when the investigators can explain how it protects participants, preserves interpretability, or defines the population needed for the research question.

The Washout Problem: Why Prior Supplements Complicate the Baseline

Vitamin D is fat-soluble, is stored in body tissues, and does not necessarily disappear on the schedule a protocol would prefer. That makes supplement washout one of the least tidy parts of recruitment. A participant may stop taking a personal product before screening, yet still arrive with a 25(OH)D concentration influenced by the preceding dose, duration of use, season, body composition, dietary intake, and sunlight exposure.

The correct response is not to pretend that every participant has the same washout curve. It is to define what the trial needs and document what the participant actually did.

Some protocols exclude non-study vitamin D use above a specified frequency, such as use on more than 15 days per month. That can be a reasonable methodological rule when the purpose is to recruit people whose recent exposure is unlikely to overwhelm the intervention contrast. But it is not a universal biological law, and it does not prove that a participant's 25(OH)D will remain above a particular threshold regardless of the time since discontinuation.

Residual 25(OH)D after supplementation can vary with the dose and duration of prior use, the interval since the last dose, adiposity, baseline status, season, diet, sun exposure, absorption, and individual metabolism. Two people reporting the same supplement frequency may therefore present with different concentrations at screening. One may remain clearly replete; another may have moved closer to the study's deficiency range. The screening result and the exposure history have to be interpreted together.

A frequent supplement user should not automatically be described as occupying the top of the distribution. Their concentration may be elevated relative to an unsupplemented participant, but the magnitude and persistence of that difference are not fixed. Nor does a reported washout period create a clean biological slate. It creates a documented interval that must be judged against the protocol's scientific and safety requirements.

What the supplement history should capture

A one-line question asking whether the participant takes vitamin D is not enough. Recruitment standards for vitamin D clinical trials should capture, as far as practical:

• the product type, including vitamin D2, vitamin D3, multivitamin, calcium–vitamin D combination, or fortified preparation;
• the reported dose and usual frequency;
• the date or approximate period of the last dose;
• whether use was daily, intermittent, seasonal, or irregular;
• changes in dose over the preceding months;
• use of prescribed preparations versus over-the-counter products;
• relevant dietary or fortified-food patterns when they are part of the study question;
• whether the participant expects to resume personal supplementation during the trial.

When records are uncertain, the uncertainty is itself data. A participant who cannot estimate the product, dose, or timing may still be eligible in a pragmatic study, but the protocol should decide whether that history belongs in a covariate, a sensitivity analysis, a stratification factor, or an exclusion rule.

The placebo question compounds the problem. In an intervention arm, it may be difficult to distinguish the response to the study capsule from the residual effect of a participant's personal routine. In a control arm, uncontrolled personal use can reduce the difference between groups. The signal-to-noise ratio becomes especially difficult to interpret when prior exposure is heavy, recent, or poorly documented.

The methodological response can take several forms:

1. Use a defined supplement restriction. Exclude or defer participants whose recent intake exceeds the protocol's prespecified limit.

2. Measure at the end of the washout rather than assuming it worked. The 25(OH)D result should remain the primary status measure, while the history provides context.

3. Record dose and timing rather than frequency alone. Fifteen days of a low-dose multivitamin is not necessarily equivalent to fifteen days of a high-dose preparation.

4. Stratify or adjust when exclusion would damage recruitment. A pragmatic trial may include prior users but analyze them separately or account for exposure in the statistical plan.

5. Repeat testing when the result is central and the first history is unreliable. This is slower, but sometimes more defensible than forcing an uncertain participant into a clean-baseline category.

A washout period of one to three months may be used in some protocols, but its adequacy is trial-specific. Longer periods can reduce residual exposure while making recruitment harder and potentially excluding the very population the study is intended to understand. Ethics review should not be treated as an obstacle to methodological purity, and methodological purity should not be used as an excuse to hide an unresolved exposure problem. The protocol has to state the trade-off.

A reported washout is an interval on the calendar, not proof of a biological reset. The relevant question is whether the exposure history and the measured baseline support the contrast your trial is designed to test.

Addressing Physiological and Clinical Exclusion Variables

Vitamin D status is shaped by more than supplement use. The participant's physiology can influence the starting concentration, the response to supplementation, and the safety of the intervention. That is why exclusion criteria for vitamin D research should be tied to the study's mechanism and endpoint rather than assembled as a generic catalogue of diseases.

Calcium and parathyroid physiology

Calcium is a basic safety variable in many vitamin D trials. A high calcium result may indicate a condition that changes the risk of supplementation, and it may require confirmation or clinical follow-up before the participant is considered for enrollment. PTH adds context because it helps describe how the body is regulating calcium and vitamin D metabolism. A low 25(OH)D with elevated PTH may fit one biological pattern; an abnormal calcium–PTH combination may suggest another.

The protocol should define what happens with borderline results. Immediate exclusion, repeat testing, physician review, or referral are different pathways. Leaving the decision to an improvised conversation at the screening desk is not a pathway.

Kidney function

Renal function can influence mineral metabolism, the conversion of vitamin D metabolites, and the safety profile of supplementation. Creatinine alone may be insufficient for the trial's purpose, particularly when body composition makes its interpretation difficult. Many protocols therefore use an estimated filtration measure or a prespecified renal-function threshold, with additional review for participants near the boundary.

Again, the threshold is not portable by default. A general-population nutrition trial and a kidney-disease trial are asking different questions. Excluding all renal impairment from one study may be appropriate; excluding it from every vitamin D study would make the evidence less useful for the patients most affected by altered mineral metabolism.

Body composition, malabsorption, and clinical history

Adipose tissue can affect the distribution and kinetics of vitamin D. Extreme body size may therefore change the dose required to achieve a given concentration or introduce additional variability into a short intervention. That does not automatically make people with obesity ineligible. It means the investigators should decide whether body size is an exclusion variable, a stratification factor, a covariate, or part of the study question.

Malabsorption, bariatric surgery, inflammatory bowel disease, cholestatic disease, and other gastrointestinal or hepatic conditions may alter absorption or metabolism. Their relevance depends on the formulation and endpoint. In a study testing oral repletion, they may be central to eligibility. In a study designed specifically for participants with malabsorption, excluding them would defeat the purpose.

Season, geography, and behavior

Sun exposure and season can move baseline 25(OH)D independently of the study capsule. Geography, clothing, occupation, travel, outdoor activity, and use of tanning facilities may also matter. These variables are often treated as background noise, but they can become important when recruitment spans months or when the intervention is modest.

The answer is not always to exclude participants with outdoor lifestyles or to recruit during one narrow calendar period. Investigators can record season and relevant exposure patterns, use stratified randomization, repeat measurements where appropriate, or include these factors in the analysis plan. The choice should be made before the results are visible.

Pregnancy and other population-specific variables

Pregnancy, breastfeeding, childhood, advanced age, frailty, and serious chronic disease each change the safety and interpretive framework. A trial should state whether these groups are excluded, studied separately, or included under a dedicated protocol. The language should be precise: a population is not methodologically unsuitable simply because it requires different monitoring.

The same applies to recent illness and medication changes. Acute disease can affect adherence, inflammation, diet, and laboratory values. Recent changes in glucocorticoids, anticonvulsants, bisphosphonates, calcium products, or other relevant therapies may influence the endpoint or the metabolism under study. The screening form should ask about timing, not just current use.

Data-Driven Recruitment: What European Trial Data Can and Cannot Tell You

A European meta-analysis of 49 primary studies covering 7,320 participants reported mean weighted baseline serum 25(OH)D concentrations of 33.01 nmol/L in intervention groups and 33.84 nmol/L in placebo groups. The median intervention duration was 136.78 days. Those figures offer useful context for recruitment, but they are not a universal template for every European trial.

They suggest that many participants in European vitamin D studies begin with relatively low measured 25(OH)D concentrations and that intervention and placebo groups can be closely balanced at baseline. They do not prove that every European adult population has the same distribution, nor do they establish that one threshold will identify the same biological group across countries, seasons, assays, and clinical settings.

The difference between the reported intervention and placebo means is small in practical terms. That is the desirable feature of a well-balanced randomized comparison, but it is not created by the screening threshold alone. It also depends on recruitment, randomization, assay quality, timing, supplement restrictions, and the handling of participants whose baseline values are uncertain.

The same body of work reported an approximate dose–response slope of 1.77 nmol/L in serum 25(OH)D per 2.5 micrograms of daily supplemental vitamin D. Such a figure can help investigators think about dose and study duration, but it should not be used as a promise for an individual participant. Dose response varies with baseline status, adherence, body composition, absorption, season, and prior exposure. A population-average slope is a planning aid, not a personal forecast.

This is where screening becomes more than a recruitment filter. Participants who begin at very low concentrations may have a different absolute and relative response from those who begin closer to the study's sufficiency range. If a protocol mixes these groups without prespecifying stratification or adjustment, the average effect can conceal clinically meaningful differences. The result may look weaker not because the intervention has no effect, but because the trial has averaged across biologically distinct starting points.

That does not justify declaring that vitamin D supplementation works in every setting. It just means that a null result is only interpretable when the baseline distribution, supplement exposure, safety markers, adherence, and endpoint are visible in the design and analysis.

Recruitment should follow the endpoint

A bone trial may prioritize fracture risk, bone turnover, calcium balance, kidney function, and medications affecting skeletal metabolism. An immune-focused trial may need a different clinical history and a different approach to recent infection or immunomodulatory treatment. A metabolic trial may define eligibility around glucose regulation, adiposity, liver status, or medication stability.

The primary keyword may be vitamin d clinical trial participant screening criteria, but there is no single screening template that serves every intervention. Eligibility criteria for vitamin D studies are meaningful only in relation to the population and outcome being studied.

A practical recruitment plan therefore asks:

• What baseline state is required to test the hypothesis?
• Which markers identify safety risks independent of vitamin D status?
• Which exposures could reduce the contrast between study groups?
• Which clinical conditions alter the mechanism or endpoint?
• Which variables should be excluded, and which should instead be measured and modeled?
• How much uncertainty in supplement history or laboratory timing can the protocol tolerate?

Those questions produce a smaller but more interpretable study population. Sometimes they also produce a larger recruitment burden. That is the cost of knowing what the intervention did.

Final Verdict: Your Trial Is Only as Good as Your Screening

A vitamin D clinical trial is a precision instrument measuring the variable response to a fat-soluble secosteroid across heterogeneous human physiology. The screening visit is where investigators decide whether that instrument will measure signal or mostly noise. Fail the screening, and a trial with an expensive intervention and an outcomes-grade endpoint can become an elaborate exercise in explaining why the groups did not separate.

Before randomization, several things need to be true.

First, baseline serum 25(OH)D must be measured, documented, and used in a way that matches the hypothesis — as an inclusion gate, a stratification factor, a covariate, or some combination of these. It should not be treated as a retrospective footnote. At the same time, the screening panel should include the safety and eligibility markers relevant to the intervention, which may include calcium, renal function, PTH, medication exposure, pregnancy status, and other clinical variables.

Second, supplement use must be handled as an exposure, not as a yes-or-no administrative detail. A washout period may be appropriate, but its duration does not guarantee that prior supplementation has stopped influencing baseline 25(OH)D. The protocol should record product, dose, frequency, timing, and uncertainty, then apply a prespecified rule that fits the trial's scientific question.

Third, clinical exclusions must protect both participants and the validity of the data. Hypercalcemia, significant renal dysfunction, relevant endocrine disease, recent medication changes, pregnancy, malabsorption, extreme body size, and other variables may require exclusion, repeat testing, or specialist review depending on the study population.

Finally, recruitment data should be interpreted rather than merely collected. European meta-analytic values can provide a useful reference for planning, but they do not replace local screening data or justify universal cutoffs. The population that actually enters the trial is the population your result describes.

Anything less is not necessarily a failed trial. It is a trial whose conclusion will carry more uncertainty than the protocol admits. Screening is where that uncertainty is either controlled, measured, or quietly allowed to become the headline.